Neurizon Therapeutics Limited has released a press release.
PharmAust canine trial update
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- PharmAust Progresses to Elevated Doses in MND Patients
- MND Trial Successfully Completes First Patient Cohort
- PharmAust Canine Trial Update clarification
- MND Trial Completes Enrolment of First Patient Cohort
- DNDi contract extension for PharmAust subsidiary Epichem
Later from Neurizon Therapeutics
- First Patient of Cohort 2 Dosed in MND Trial
- European Patent relating to MPL Combinations in Cancer
- Interim analysis recommended in MND trial
- Canine Cancer Trial Update
- Stable Patient in MND trial reaches 6-months on MPL
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics